JPMorgan initiated coverage of Opko Health (OPK) with a Neutral rating and no price target The firm says Opko is a “multi-faceted” healthcare company, focusing in clinical diagnostics services through BioReference Labs operations and therapeutics development through its ModeX subsidiary. The company’s clinical-stage pipeline portfolio remains early stage and needs clinical validation before “buy-in from investors,” the analyst tells investors in a research note. JPMorgan awaits clinical validation before recommending the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPK:
- Hold Rating on Opko Health Amid Early-Stage Therapeutic Pipeline and Strategic Shift
- Insider Moves: Crown Castle, Serve Robotics, Las Vegas Sands, Opko Health, and Interactive Brokers Stocks in Focus
- Starbucks, Opko Health, Roblox, Cloudflare, Apple: Trending by Analysts
- Opko Health’s Strategic Moves Highlighted in Earnings Call
- Opko Health downgraded to Hold from Buy at Jefferies